Search for Clinical Trial Results

Sponsored By

Indolent B Cell Lymphoma - 25 Studies Found

Status Study
Recruiting Study Name: Sofosbuvir+Ledipasvir ±Ribavirin and Sofosbuvir+Ribavirin for Pts With Indolent Bcell Lymphoma Associated With HCV Infection Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin(G1, 3 and 4) and Sofosbuvir+Ribavirin(G2) for Pts With Hepatitis C Virus Associated Indolent B-cell Lymphomas
Condition:
  • Indolent B-cell Lymphoma
  • Hepatitis C

Date: 2016-02-25
Interventions:
  • Drug: Sofosbuvir+Ledipasvir

Completed Study Name: High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas
Condition:
  • B-cell Lymphoma
  • Indolent B-cell Lymphoma

Date: 2009-05-06
Interventions: Drug: rituximab Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosi
Recruiting Study Name: Indolent Non Follicular Lymphomas Prognostic Project
Condition: Indolent B-Cell Lymphomas
Date: 2016-09-06
Interventions: Other: Any treatment, watch and wait policy included Patients registered in the study despite their plan
Recruiting Study Name: Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
Condition:
  • Chronic Lymphocytic Leukemia
  • Indolent B-cell Lymphomas
    • Date: 2016-12-02
    Interventions: Drug: Ibrutinib Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (l
Active, not recruiting Study Name: Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Condition:
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Small Lymphocyt
    Date: 2010-11-10
    Interventions: Drug: ofatumumab Weekly infusion for 8 weeks Other N
Recruiting Study Name: Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma
Condition: Lymphoma
Date: 2015-07-08
Interventions: Radiation: Radiation Therapy Participants receive radiation to entire involved orbit for a total dose of
Recruiting Study Name: Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Condition:
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • Nodal Marginal
    Date: 2014-01-28
    Interventions:
    • Drug: PI3K inhibitor BKM120 Wi
Completed Study Name: VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Condition:
  • B-Cell Lymphoma
  • Follicular Lymphoma
  • Marginal Lymphoma

    • Date: 2004-06-11
    Interventions: Drug: VELCADE and rituximab
Withdrawn Study Name: Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
Condition:
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Follicular
  • Lymphoma, B-Cel
    Date: 2010-12-16
    Interventions: Drug: Ofatumumab Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
Not yet recruiting Study Name: Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Condition:
  • B Cell Lymphoma
  • Lymphoma

Date: 2016-09-08
Interventions:
  • Drug: Ixazomib The prescribed

Next >>>